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Abstract
Background: In vivo efficacy assessments of antimalarials are essential for ensuring effective case management. In Ethiopia,
chloroquine (CQ) without primaquine is the first-line treatment for Plasmodium vivax in malarious areas, but artemether-
lumefantrine (AL) is also commonly used.
Methods and Findings: In 2009, we conducted a 42-day efficacy study of AL or CQ for P. vivax in Oromia Regional State,
Ethiopia. Individuals with P. vivax monoinfection were enrolled. Primary endpoint was day 28 cure rate. In patients with
recurrent parasitemia, drug level and genotyping using microsatellite markers were assessed. Using survival analysis,
uncorrected patient cure rates at day 28 were 75.7% (95% confidence interval (CI) 66.8–82.5) for AL and 90.8% (95% CI 83.6–
94.9) for CQ. During the 42 days of follow-up, 41.6% (47/113) of patients in the AL arm and 31.8% (34/107) in the CQ arm
presented with recurrent P. vivax infection, with the median number of days to recurrence of 28 compared to 35 days in the
AL and CQ arm, respectively. Using microsatellite markers to reclassify recurrent parasitemias with a different genotype as
non-treatment failures, day 28 cure rates were genotype adjusted to 91.1% (95% CI 84.1–95.1) for AL and to 97.2% (91.6–
99.1) for CQ. Three patients (2.8%) with recurrent parasitemia by day 28 in the CQ arm were noted to have drug levels above
100 ng/ml.
Conclusions: In the short term, both AL and CQ were effective and well-tolerated for P. vivax malaria, but high rates of
recurrent parasitemia were noted with both drugs. CQ provided longer post-treatment prophylaxis than AL, resulting in
delayed recurrence of parasitemia. Although the current policy of species-specific treatment can be maintained for Ethiopia,
the co-administration of primaquine for treatment of P. vivax malaria needs to be urgently considered to prevent relapse
infections.
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Introduction
Plasmodium vivax transmission is more widely distributed globally
than P. falciparum, with 2.85 billion people living at risk of its
infection [1]. In Ethiopia, malaria is a leading cause of morbidity
and mortality, with 14% of all outpatient visits and 9% of hospital
admissions being due to malaria in 2009–2010 [2]. Unlike much of
Africa, both P. falciparum and P. vivax substantially contribute to
malaria morbidity in Ethiopia, in relative proportions of approx-
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imately 60% and 40% [3,4,5], respectively, although their relative
proportions vary both temporally and spatially.
With wide-spread P. falciparum resistance to chloroquine (CQ)
[6] and sulphadoxine-pyrimethamine (SP) [7,8], in 2004, the
Ethiopian Federal Ministry of Health (FMOH) adopted arte-
mether-lumefantrine (AL) as first-line treatment of uncomplicated
P. falciparum malaria and of mixed infections with both P. falciparum
and P. vivax [9]. Although CQ remains the first-line treatment for
P. vivax malaria in Ethiopia, AL is used widely for all cases of
mixed infections and clinical malaria where laboratory diagnostics
to determine the specific malaria species are not available or not
done.
Following the first report of CQ-resistant P. vivax in 1989 from
Papua New Guinea [10], decreased CQ susceptibility have been
reported from Indonesia [11,12,13,14], Papua New Guinea [15],
Burma [16], Vietnam [17,18], Turkey [19,20], Colombia [21],
and Brazil [22]. Overall, CQ-resistant P. vivax has remained rare
in Africa. In 1996, Ethiopia published its first report of CQ
resistance, with 2% (5/255) of study patients on CQ with
persistent parasitemia on day 7 [23]. Subsequent reports from
Ethiopia documented presence of CQ-resistant P. vivax, but at
levels not exceeding 5% [24,25,26].
After adopting AL as first-line therapy for uncomplicated P.
falciparum malaria, mixed infections, and clinically diagnosed
malaria, the Ethiopian FMOH scaled up an ambitious plan to
provide universal access to prompt malaria diagnosis and
treatment –as recommended by the World Health Organization
(WHO) [27]– through a network of 15,000 community-level
health posts [28]. With the use of multi-species malaria rapid
diagnostic tests (RDTs) to distinguish P. falciparum from P. vivax
infection and expansion of quality malaria microscopy diagnostic
capacity, administration of CQ increased in Ethiopia since 2004 in
parallel with increased numbers of laboratory confirmed P. vivax
mono-infections. Since both AL and CQ without primaquine are
widely used according to FMOH guidelines for P. vivax infections
in malarious areas, continuously monitoring in vivo drug efficacy to
these medications for P. vivax malaria is recommended by WHO
[29,30] to allow for sufficient time to explore alternatives and
change national policy when efficacies are observed to decline.
The objectives of the study reported here were (i) to assess the
in vivo efficacy of AL and CQ for treatment of P. vivax for 28 days,
and (ii) to assess secondary outcomes of day 42 efficacy,
hematologic response, and fever and parasite clearance rates.
Methods
The protocol of this trial and supporting CONSORT checklist
are available as supporting information (see Protocol S1 and
Checklist S1).
Study Site and Enrollment
This randomized, open-label study was conducted at two
established FMOH health facilities, the Bishoftu Malaria Clinic
and the Bulbula Health Center, in Oromia Regional State,
Ethiopia, from October 2009 to January 2010. P. falciparum and P.
vivax are endemic in the catchment areas of both sites, and the
study was conducted during the peak malaria transmission season
which occurs between September to December. Detailed study site
information has been previously reported along with the results of
the P. falciparum treatment outcomes [31].
Patients
Patients with P. vivax mono-infection, with parasitemia density
.250 asexual forms per ml were enrolled. Additional inclusion
criteria included age .6 months, weight .5 kg, and axillary
temperature $37.5uC or history of fever in the past 48 hours.
Only patients living within 20 km of the facilities were enrolled in
the study to facilitate follow-up. Exclusion criteria included
detection of any Plasmodium sp. infection besides P. vivax mono-
infection, any signs or symptoms of severe illness, severe
malnutrition, severe anemia (hemoglobin,5 g/dL), known hy-
persensitivity to AL or CQ, pregnancy, breastfeeding, or presence
of another infection or major co-morbid conditions by history.
The study received ethical clearance from the U.S. Centers for
Disease Control and Prevention, Columbia University, and the
Ethiopian Public Health Association. Written informed consent
was obtained from adult patients and guardians of enrolled
children. Written assent was also obtained from children 7–17
years of age.
Clinical and Laboratory Procedures
To assess AL and CQ therapeutic efficacy for uncomplicated
P. vivax mono-infection based on clinical and parasitological
parameters, we conducted a prospective, 42-day, randomized,
open-label in vivo efficacy assessment according to the 2003 and
2009 WHO in vivo protocol for measuring antimalarial drug
efficacy for areas of low to moderate malaria transmission [29,30].
At the Bishoftu Malaria Clinic, blood films were taken at initial
presentation for all patients (as routinely done). Once a positive P.
vivax infection was identified by microscopy, the patient was
screened for study eligibility criteria. At Bulbula Health Center, all
patients attending the outpatient ward were initially clinically
evaluated by the health facility staff; those with fever or a history of
fever were referred for malaria microscopy testing (as routinely
done). Once the patient was noted to have microscopy-confirmed
P. vivax infection, the study staff screened the patient for inclusion
in the study.
After meeting the inclusion criteria and consenting to study
enrollment, all patients underwent hemoglobin testing (Hemocue
Hb 201+, Angelholm, Sweden) and filter paper blood spot
collection. All women aged 13–49 years underwent a urine
pregnancy test and those testing positive were excluded from the
study. Giemsa-stained thick and thin blood films were prepared
according to standard procedures [29] and read by two
independent microscopists blinded to the other read and the
assigned treatment arms. Parasite density was estimated based on
the number of asexual parasites observed against 200 leukocytes
assuming 8,000 leukocytes per ml. Slides with parasite densities
differing by more than 20% between microscopists were reassessed
by a third microscopist, with the third reading considered final.
Smears were determined to be negative only after examining 100
high power oil immersion fields.
Patients were enrolled, interviewed and examined by the study
clinician. The patients were randomized to standard dosages of
oral AL (CoartemH, Novartis Pharma, Basel, Switzerland) or CQ
(AralenH, Sanofi-Aventis, US) based on weight according to
national policy [9]. Randomization sequence was computer
generated by the principal investigator and kept in sealed
envelopes. Clinicians enrolled the patients and nurses assigned
the patients sequentially according to the sealed envelopes.
Artemether-lumefantrine was packaged in fixed-dose combination
tablets, each containing 20 mg of artemether and 120 mg of
lumefantrine. Artemether-lumefantrine was administered accord-
ing to the package insert twice daily for three days: patients
weighing 5–14 kg, 15–24 kg, 25–34 kg, and $35 kg were given
one tablet, two tablets, three tablets, and four tablets at each of six
dosing intervals, respectively. The initial and each morning dose
were directly observed by the study staff and given with milk
Artemether-Lumefantrine and Chloroquine Efficacy
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biscuits to increase absorption [32,33]. A total of 25 mg base per
kg over three days (10 mg base/kg on day 1 and 2, and 5 mg
base/kg on day 3) of CQ was administered based on weight using
10 mg/ml syrup or dividing 500 mg tablets accordingly. All
patients were monitored for 60 minutes; a full or half a dose was
re-administered if the patient vomited the drug within 30 or 31–60
minutes, respectively. If the patient vomited again, he or she was
referred to the hospital and withdrawn from the study. Patients
were instructed to take the evening dose with food. On follow-up
days 1–3, patients taking AL were asked if the drug was taken
properly the previous night. In order to facilitate twice daily dosing
of AL, all patients presenting after 1500 hrs were excluded from
the study. Antipyretics were given for temperatures .39uC as per
national policy [9]. Ferrous sulfate, folate, and mebendazole (if
aged .1 year) were given to all children with hemoglo-
bin,10 mg/dl as per Integrated Management of Childhood
Illness guidelines [34]. Quinine (10 mg mg/kg every 8 hours for 7
days), the second-line treatment as per national policy [9], was
administered as rescue therapy.
Follow-up
Patients were followed-up for 42 days and asked to return on
days 1–3, 7, 14, 21, 28, 35, and 42 post-treatment, as well as any
other interim day if ill. The study site facilities were open from
0800 to 1800 hrs, and after hours care was also available.
Standardized follow-up included documentation of history-taking
to elicit symptoms, adverse events, and any concomitant therapy,
and physical examination including axillary temperature mea-
surement. All symptoms elicited during follow-up that were not
present on day 0 were classified as an adverse event. For all
adverse events, severity, duration, outcome and its likely related-
ness to the administered drug were assessed by the clinicians.
Adverse events were reported for all enrolled patients. Finger
pricks for follow-up blood films were taken on scheduled days 2, 3,
7, 14, 21, 28, 35, 42, and at any unscheduled visit. Hemoglobin
was measured weekly and filter papers were collected on day 7 for
drug level testing and on any day of recurrent parasitemia (after
day 3) for CQ level and parasitemia molecular testing. All filter
papers were dried and stored in plastic storage bags with desiccant
and humidity indicators. The filter papers for drug level and
molecular testing were sent to the U.S. Centers for Disease
Control and Prevention in Atlanta, USA. All additional sample
investigations such as the drug level and molecular testing were
performed by individuals who were blinded to the treatment
allocation.
Outcomes
Efficacy was assessed by clinical and parasitological outcomes
using WHO definitions, with a 42-day follow-up period [30], with
treatment failure defined as 1) clinical deterioration due to P. vivax
illness requiring hospitalization in presence of parasitemia; or 2)
presence of parasitemia and axillary temperature $37.5uC
anytime between days 3 and 28/42; or 3) presence of parasitemia
on any day between days 7 and 28/42, irrespective of clinical
conditions. If no failure was recorded, outcome was classified as a
treatment success.
Laboratory Analysis
To refine the identification of recrudescences, three to four
drops of blood were collected on filter paper at day 0 prior to
treatment, day 7, and on any day of recurrent parasitemia. Blood
spots collected on the day of enrollment (day 0) and on the day of
failure were used for molecular analysis to determine the genetic
identity of the parasites. Blood spots collected on day 7 or day of
treatment failure were tested for lumefantrine and CQ drug levels,
respectively.
Microsatellite characterization. Eight of the eleven micro-
satellite markers described by Imwong et al. [35] were chosen for
the final analysis in this study. Although marker 2208 amplified
only in a subset of samples, it was included in the final analysis,
because allelic difference in this locus was useful to differentiate
strains. The published PCR protocol [35] was slightly modified by
using a commercial PCR MasterMix (Promega, Madison, WI).
Length variation in fluorescently-labeled PCR products was
determined on an Applied Biosystems Prism 31306l Avant
Genetic Analyzer and the data analyzed using GeneMapper
v4.0 (all Applied Biosystems, Foster City, CA). When the sizes of
alleles at a microsatellite marker differed by .2 base pairs, they
were considered different alleles.
The genetic variation for each microsatellite locus was
measured by calculating the expected heterozygosity (He) and
number of alleles per microsatellite locus (A). He was calculated for
each locus as He = [n/(n–1)][1–gpi
2], where n is the number of
isolates sampled and pi is the frequency of the ith allele. The




2)2]] [36]. Arlequin ver 3.01 (University of Bern, Switzerland)
was used to compute He [37], and the Excel Microsatellite Toolkit
was used to format data for use in Arlequin [38]. When parasites
on day 0 and the day of failure were different from each other at
one or more loci in their microsatellite profile, then these parasites
were considered genetically non-identical and regarded as
different strains for the purpose of this study. Recurrent
parasitemias with identical genotypes from day 0 were classified
as recrudescences (true drug resistance) although this group could
include homologous relapses. The PCR-adjusted cure rate (the
sum of cases with no recurrent parasites and recurrent with
different genotypes) attempts to reduce the contribution from new
infections and heterologous relapses representing a refined
‘minimum’ cure rate.
Drug level testing. Lumefantrine levels from day 7 dried
blood spots were assessed in all cases of AL recurrent parasitemia.
Lumefantrine levels in capillary whole blood were measured from
dried blood spots using a modified high-performance liquid
chromatographic method [30]. Due to logistical constraints, it
was impossible to treat the filter papers with tartaric acid prior to
blood application as suggested by Blessborn et al. [30], resulting in
a lower recovery efficiency and a higher limit of quantification of
212 ng/ml.
Similarly, CQ levels from dried blood spots collected on the day
of failure were assessed in all cases of CQ treatment failure.
Chloroquine and its metabolite, desethylchloroquine (DCQ), were
measured using a high-performance liquid chromatographic
method as described by Patchen et al. [39]. The limit of detection
for both CQ and DCQ was 5 ng/ml. Levels,5 ng/ml were
designated as below detection.
Statistical Analysis
Primary efficacy outcome was day 28 cure rates. Secondary
outcomes included day 42 cure rates, genotype adjusted minimum
cure rates, hematologic outcomes, and fever and parasite
clearance. With treatment failure of AL and CQ for P. vivax
being reported at #5%, 10% was chosen as the estimated
therapeutic failure rate. Assuming an estimated cure rate of 90%
and a 20% loss to follow-up at 42 days, a sample size of 120
subjects per arm was calculated to result in a 95% exact binomial
confidence interval from 82.4%–95.1%. The study was not
powered to estimate differences in efficacy across treatment arms
or between sites.
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All data were entered into both a Microsoft Access (Microsoft,
Redmond, WA, USA) study database and the Microsoft Excel
(Microsoft, Redmond, WA, USA) standard database developed by
WHO [30], and analyzed using SAS 9.2 (SAS Institute, Cary, NC,
USA). Data were double-entered and any discrepancies resolved
by referring to the original paper form. The cumulative risk of
failure was computed for 28 and 42 days of follow-up using a
modified intention to treat Kaplan-Meier survival analysis, the
most appropriate way to estimate failure rates: parasitological
recurrence is classified as treatment failure on the day it occurred
[40], where lost to follow-up, withdrawals, and parasitemia with a
different species are censored on the last day of follow-up. For
survival analyses adjusting for microsatellite results, isolates with
different genotype for primary and recurrent parasitemias were
censored on the last day of recurrence. Comparisons between
groups were made using a x2 test or Fisher’s exact test for
categorical variables and the Student’s t-test or Wilcoxon-Mann-
Whitney test for continuous variables. A two-sided p-value,0.05
was considered statistically significant.
Results
Patients
Of the 4,426 patients tested from the two study sites, 961 were
positive for malaria parasites from October 21 to November 30,
2009. The last date of follow-up occurred on January 11, 2010. Of
672 patients with confirmed P. vivax mono-infections, 242 (217
from Bishoftu and 25 from Bulbula) were enrolled for the in vivo
drug efficacy study, with 122 and 120 patients randomized to
receive AL or CQ, respectively (Figure 1). At the Bishoftu Malaria
Clinic where all presenting patients received microscopy testing,
the slide positivity rate was 16.5% (455/2,764), of which P. vivax
mono-infection accounted for 83.5% (380/455). At Bulbula
Health Center where only suspected malaria cases received
microscopy, the slide positivity rate was 30.7% (510/1,662) of
which P. vivax mono-infection accounted for 57.3% (292/510).
The majority of excluded patients presented late in the afternoon
and was therefore not enrolled to ensure appropriate timing of the
second AL dose.
Although drug assignment was randomized, there was a
statistically significant baseline difference in age (p = 0.03), weight
(p = 0.04), height (p = 0.05), and ownership of bed nets with fewer
patients in the AL drug arm owning one (p = 0.02) (Table 1). The
other characteristics did not differ significantly, but the study was
not powered to compare the drug arms.
Treatment Outcomes
Follow-up was completed for 114 patients to day 28 and 113 to
day 42 in the AL arm and 108 patients to day 28 and 107 to day
42 in the CQ arm (Figure 1). Six of 122 patients were lost to
follow-up and three withdrew from the study in the AL arm,
whereas, ten of 120 patients were lost to follow-up and three
withdrew from the CQ arm (Table 2). The total attrition rate was
8.0% for the AL arm and 12.1% in the CQ arm.
Treatment with both AL and CQ resulted in rapid clearance of
parasites and reduction of fever. Whereas in the AL arm all
patients had cleared their peripheral parasitemia by day 2, 6.0%
(7/117) of the patients in the CQ arm had peripheral parasitemia
by day 2 and 0.9% (1/115) remained positive on day 3 (Table 3).
The difference in day 2 positivity was statistically significant
(p = .006). Of those with persistent peripheral parasitemia on day
2, one was lost to follow-up, but the remaining with outcome data
did not develop recurrent parasitemia.
In the AL arm, 28 patients (24.3%) presented with recurrent
parasitemia by day 28, and 47 (41.6%) by day 42 (Table 2). In the
CQ arm, ten patients (9.3%) presented with recurrent parasitemia
by day 28 and 34 (31.8%) by day 42 (Table 2). The median time to
appearance of recurrent parasitemia was 28 days (range 21–42) in
the AL arm and 35 days (range 21–42) in the CQ arm (Table 3).
The earliest day of recurrent parasitemia was day 21 for both
treatment arms. The PCR uncorrected cure rates at day 28 and 42
in the AL arm were 75.7% (95% CI 66.8–82.5) and 58.8% (95%
CI 49.2–67.2), respectively (Table 2 and Figure 2A).The uncor-
rected cure rates at day 28 and 42 in the CQ arm were 90.8%
(95% CI 83.6–94.9) and 68.4% (95% CI 58.7–76.3), respectively
(Table 2 and Figure 2A). The day 28 PCR uncorrected cure rate
for the CQ arm was higher than the AL arm, which was
statistically significant (p = 0.003). The varying proportion of
patients presenting with recurrent parasitemia and the cure rates
by study site are shown in Table 2 which suggests higher recurrent
parasitemia rates in Bishoftu. However, with such small number of
patients from Bulbula the confidence intervals are too wide to
draw any meaningful conclusions.
In the AL arm, the median age for those patients with or
without recurrent parasitemia was seven and 17.5 years of age,
respectively (p,0.0001). In the CQ arm, the median age for those
patients with or without recurrent parasitemia was nine and 20
years of age, respectively (p,0.0001). In both treatment arms,
younger age was associated with treatment failure. In the CQ arm,
those with recurrent parasitemia had a higher median parasite
density (4780 parasites/mL) compared to those without recurrent
parasitemia (2120 parasites/mL) which was statistically significant
(p = 0.01).
Laboratory Outcomes
Hematologic response. In the AL arm, median hemoglobin
increased from 13.0 g/dL (standard deviation (SD) 2.3) on day 0
to 13.9 g/dL (SD 1.5) on day 42 (Table 3). In the CQ arm,
median hemoglobin increased from 13.5 g/dL (SD 2.5) on day 0
to 14.2 g/dL (SD 1.8) on day 42. The difference in median
hemoglobin levels between day 42 and 0 was 0.06 g/dL (SD 0.18)
in the AL arm and 0.06 g/dL (SD 0.17) in the CQ arm.
Microsatellite analysis of paired samples. Day 0 and day
of recurrent parasitemia samples were analyzed for P. vivax strain
identity using the size polymorphisms in eight microsatellite loci as
reported in Table 4. For the AL arm, 47 pairs were analyzed and
16 pairs were identical at all loci (Table 2). For the CQ arm, 34
pairs were analyzed and 16 pairs were identical at all loci. It is
worth noting that most of the microsatellite markers used in this
study (except marker 2208) were highly diverse as indicated by
high HE values and several allelic forms existed for all the markers
used in this study (Table 4). This data provide further support that
these combination of markers can reliably differentiate genetic
relatedness of parasite populations in this study. Since paired
samples identified as different strains are not true drug resistant
infections, the PCR adjusted cure rates for the AL arm at day 28
were refined from 75.7% to 91.1% (95% CI 84.1–95.1) and for the
CQ arm from 90.8% to 97.2% (95% CI 91.6–99.1) (Table 2). The
day 42 PCR adjusted cure rates were 84.3% (95% CI 75.6–90.1)
for the AL arm and 83.6% (95% CI 74.6–89.7) for the CQ arm
(Table 2 and Figure 2B). Overall, 49 pairs were different in at least
one locus and they were considered different strains (Table S1).
Drug level testing. Day 7 whole blood capillary lumefan-
trine levels from dried blood spots for the patients in the AL arm
with recurrent parasitemia ranged from below detection to
1,537.3 ng/mL (median 446.3 ng/mL). Using previously reported
cut-off levels identified to predict P. falciparum treatment failure of
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,280 ng/ml [33] and ,175 ng/ml [41], 30.4% (14/46) and
19.6% (9/46) of the recurrent samples were below this level,
respectively.
Chloroquine and DCQ levels on the day of recurrent
parasitemia in the CQ arm ranged from below detection to
485.1 ng/mL. Of those that had recurrent parasitemia by day 28,
30% (3/10) were noted to have CQ+DCQ levels above the
minimum effective concentration (i.e. 100 ng/mL). Thus, 2.8%
(3/108) of all patients had recurrent parasitemia by day 28 with
adequate CQ blood levels, suggesting P. vivax CQ resistance. Of
the three recurrent parasitemias with adequate CQ concentra-
tions: one was caused by the identical P. vivax strain (3-year-old
boy) and two were caused by different P. vivax strains (7- and 2-
year-old boys).
Adverse Events
Both AL and CQ were well tolerated with no serious adverse
events reported. Overall, 48.4% (59/122) of the patients in the AL
arm and 50.8% (61/120) in the CQ arm reported at least one
adverse event. 8.2% (10/122) of the patients in the AL arm and
12.5% (15/120) in the CQ arm presented with oral ulcers, which
Figure 1. Trial Profile. Screening, Enrollment, and Follow-up of Patients.
doi:10.1371/journal.pone.0063433.g001
Table 1. Baseline characteristics of enrolled patients by treatment group.
Artemether-lumefantrine Chloroquine
Characteristic N = 122 N = 120
Female, n (%) 46 (37.7%) 38 (31.7%)
Median age, years (range) 11.5 (1–70) 18 (1–65)
Median height, cm (range) 144 (70–183) 159 (75–190)
Median weight, kg (range) 30 (6–79) 48.5 (8–76)
Median temperature, uC (range) 37.0 (35–40.5) 37.0 (35–40.3)
Median hemoglobin, g/dL (range) 13.0 (5.7–17.6) 13.5 (6.9–18)
Geometric Mean Parasite Density (range) 3179 (280–28,400) 2561 (280–42,000)
Owns a bednet, n (%) 51 (41.8%) 68 (56.7%)
IRS in past 12 months, n (%) 64 (52.5%) 72 (60%)
doi:10.1371/journal.pone.0063433.t001
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was the most common complaint, followed by nausea/vomiting
and cough (Table 5).
Discussion
We show that both AL and CQ are well-tolerated and remain
efficacious for early P. vivax treatment response involving 242
patients from two sites in central Ethiopia in late 2009. In both
treatment arms, no recurrent parasitemias were seen prior to 21
days and there were very few patients that remained microscopy
positive beyond day 2 in contrast to high rates of day 2 and 3
positivity seen in Asia with known high grade CQ resistance
[13,42]. Albeit low, the CQ arm had higher day 2 positivity
compared to the AL arm, which is consistent with conclusions
from a recent review of ACTs for P. vivax treatment which noted
that patients receiving ACTs clear their parasites more quickly
(median parasite clearance time = 28.8 hrs) compared to CQ-
based monotherapy or non-ACT combination therapies (50.4 hrs)
[43].
Although high rates of recurrent parasitemia were noted in both
treatment arms, fewer patients receiving CQ presented with
recurrent parasitemia by day 28 compared to those receiving AL
indicating that CQ may have provided longer post-treatment
prophylaxis. Our recurrent P. vivax parasitemia findings are higher
than some previously reported studies in Ethiopia [24,25,44], but
Table 2. Treatment outcomes after day 28 and 42 of follow-up by treatment arm.
Artemether-lumefantrine (n = 122) Chloroquine (n = 120)
Outcome Day 28 Day 42 Day 28 Day 42
No treatment outcome, n (%) 8 (6.6) 9 (8.0) 12 (11.1) 13 (12.1)
Lost to follow-up 6 6 9 10
Protocol violation 2 3 3 3
Recurrent parasitemia, n (%) 28 (24.3) 47 (41.6) 10 (9.3) 34 (31.8)
Bishoftu, n/N (%) 28/115 (24.4) 46/115 (40) 8/102 (7.8) 30/102 (29.4)
Bulbula, n/N (%) 0/7 (0) 1/7 (14.3) 2/18 (11.1) 4/18 (22.2)
Cure rate–Survival analysis, % (95% CI) 75.7 (66.8–82.5) 58.8 (49.2–67.2) 90.8 (83.6–94.9) 68.4 (58.7–76.3)
Bishoftu, % (95% CI) 74.6 (65.4–81.7) 57.9 (48.1–66.5) 91.2 (83.1–95.5) 66.7 (56.0–75.4)
Bulbula, % (95% CI) 100 80.0 (20.4–96.9) 88.9 (62.4–97.1) 77.0 (49.7–90.7)
Genotype of recurrent parasitemias, n (%)
Different* 18 (64.3) 31 (66.0) 7 (70.0) 18 (52.9)
Identical 10 (35.7) 16 (34.0) 3 (30.0) 16 (47.1)
Minimum cure rate (adjusted for genotype*)–Survival analysis,
% (95% CI)
91.1 (84.1–95.1) 84.3 (75.6–90.1) 97.2 (91.6–99.1) 83.6 (74.6–89.7)
*Greater than 2 base pair difference detected in at least one out of eight markers between the Day 0 (pre-treatment) and day of failure samples.
CI- confidence interval.
doi:10.1371/journal.pone.0063433.t002
Table 3. Secondary outcomes by treatment arm.
Outcome Artemether-lumefantrine Chloroquine
Fever, n/N (%)*
Day 1 76/122 (62.3) 66/118 (55.9)
Day 2 31/121 (25.6) 26/117 (22.2)
Day 3 13/121 (10.7) 11/115 (9.6)
Parasitemia, n/N (%)
Day 2 0/121 (0) 7/117 (6.0)
Day 3 0/121 (0) 1/115 (0.9)
Days to recurrence, median (Range) 28 (21–42) 35 (21–42)
Median Hemoglobin g/dL, mean (SD)
Day 7 12.5 (1.7) 13.2 (2.0)
Day 28 13.7 (1.7) 14.0 (1.7)
Day 42 13.9 (1.5) 14.2 (1.8)
Median difference in hemoglobin from day 0 to day 7 0 (0.1) 20.02 (0.1)
Median difference in hemoglobin from day 0 to day 42 0.06 (0.18) 0.06 (0.17)
*Subjective fever or axillary temperature $37.5uC; CI- confidence interval.
doi:10.1371/journal.pone.0063433.t003
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are consistent with more recent efficacy studies from 2005 and
2009 [26,45]. Similarly, observed recurrent parasitemia rates with
AL and CQ are comparable to reports from the Greater Mekong
Sub-region [16,17,46,47], but not as high as the Southwest Pacific
region where rapidly relapsing tropical strains, high grade CQ
resistance, and high rates (i.e. 57–70%) of recurrence within 28–42
days following AL administration are common [11,14,42]. Even
though confirmed CQ resistance appears to be at ,5% in our
study consistent with others from Ethiopia that included CQ drug
level testing [24–26], the confirmation of resistant strains, the
relatively high recurrent rate seen by day 28 and other reports
from elsewhere in Ethiopia of parasitemia recurrences occurring as
early as day 7 [45] are all concerning for the possibility of evolving
CQ resistance. Continued monitoring involving additional sites is
needed to understand the efficacy of antimalarial drugs in
Ethiopia, and it is possible that focal drug resistance could emerge
within a large and populous country such as Ethiopia.
Figure 2. Kaplan-Meier Survival Curves for time to recurrent parasitemia during the 42 days of follow-up. (A) Time to any recurrent P.
vivax parasitemia by drug arm; (B) Time to only recurrent P. vivax parasitemia with the same genotype by drug arm. AL: artemether-lumefantrine; CQ:
chloroquine.
doi:10.1371/journal.pone.0063433.g002
Table 4. Microsatellite diversity for eight potential markers for P. vivax by pre- and post-treatment.
Microsatellite marker name 14.185 12.335 7.67 2208 8.332 6.34 10.29 3.35
Microsatellite v23 v24 v25 v27 v29 v30 v32 v33
Allelic size range, bp
D0 263–273 156–196 100–125 158–169 216–252 136–173 116–130 112–128
DF 263–283 155–196 100–125 159–169 231–252 135–173 115–134 112–128
No. of alleles
D0 8 11 18 6 12 16 10 11
DF 7 15 18 4 13 18 11 13
PCR positivity
D0 82 79 73 39 80 81 82 82
DF 82 79 67 25 81 81 80 81
MOI
D0 0 2 13 0 3 3 0 8
DF 1 2 11 0 3 1 0 1
HE
D0 0.821 0.818 0.774 0.631 0.836 0.864 0.820 0.757
DF 0.816 0.828 0.856 0.504 0.834 0.867 0.818 0.773
Microsatellite markers and their descriptions are as reported previously [35]. bp- base pairs; D0- day 0; DF- day of failure; No.- number; PCR- polymerase chain reaction;
PCR positivity indicates number of samples successfully amplified for the indicated loci. MOI- multiplicity of infection, minimum number of different parasite genotypes
present; HE-expected virtual heterozygosity where HE = [n/(n –1)] X(1– gp
2i), where n is the number of samples. This variable can be defined as the probability that a
randomly chosen pair of alleles differ from each other.
doi:10.1371/journal.pone.0063433.t004
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Our study also highlights issues related to classifying recurrent
parasitemia using molecular methods. Although genotyping to
distinguish recurrent parasitemias in P. vivax in vivo studies is not
standardized and is not part of the current standard WHO
protocol [30], it has been used to improve characterization of
recurrent P. vivax parasitemias [16,18,48,49]. The combination of
microsatellite markers used in our study reliably differentiated
genetic relatedness of parasite populations allowing us to better
estimate the true efficacy of P. vivax treatment regimens. Recurrent
infections with the same genotype (true failure and homologous
relapse) were distinguished from those with a different genotype
(reinfection or heterologous relapse). Despite the possibility of a
recurrent parasitemia arising from a clonal hypnozoite, all
identical recurrent parasitemias were classified as treatment
failures resulting in a higher, more conservative estimate of
treatment failure, but still an improvement over the unadjusted
treatment failure rates.
Chloroquine drug level testing on the day of failure as
recommended by WHO to identify CQ resistance [30] was
helpful in documenting that three out of the ten recurrent
parasitemias by day 28 in the CQ arm occurred with CQ+DCQ
levels above the minimal effective concentration (i.e. 100 ng/mL
of whole blood) [50]. Although, day 7 lumefantrine levels were
determined in patients with recurrent parasitemias in the AL arm,
the utility of obtaining lumefantrine levels from filter paper to aid
in accurately determining treatment failures especially for P. vivax
remains challenging and was of limited benefit in this study.
Approximately half of the patients in both the AL and CQ
reported some adverse events, none were severe and most were
consistent with ones generally reported [51,52,53], i.e. headaches
and nausea/vomiting for AL, and headaches, vomiting, myalgia,
and pruritus for CQ. Although we noted oral lesions in both
treatment arms, this is not a previously reported common drug
side-effect and unlikely to be drug-related.
There are several limitations of this trial including drug
administration procedures, baseline differences, and external
validity. Due to logistical reasons, the evening doses of AL were
not supervised and the antimalarial treatment administration not
blinded. The lower day 28 cure rates seen in the AL arm most
likely resulted from its shorter post-prophylactic effect, but poor
adherence cannot be discounted as a contributing factor, even
though, all patients reported having taken their evening doses.
Reassuringly, approximately 70% of the patients with recurrent
parasitemia had lumefantrine levels .280 ng/mL as compared to
only 51% in a study with supervised artemether-benflumetol
administration [33]. Although treatment allocation was random-
ized, the patients in the AL arm were younger than the CQ arm.
With the finding that younger age was associated with higher
recurrent parasitemia, the contribution of this patient character-
istic in the lower AL cure rates by day 28 needs to be considered.
Results from this study may not be applicable to other ACTs or
other areas with different resistance and relapse patterns.
Furthermore, our study was not powered to estimate differences
in efficacy across treatment arms or between sites. Finally, the two
health facilities were not chosen randomly and thus may not be
representative of our target population.
Some experts have suggested unifying malaria treatments under
a single ACT regimen [43,54] in countries where P. falciparum and
P. vivax are sympatric. However, due to a relative short half-life,
AL provides less post-exposure prophylaxis against P. vivax
recurrent parasitemias. In Indonesia, patients receiving DP
compared to AL were half as likely to be anemic and 6.6 times
less likely to carry P. vivax gametocytes [53]. In a setting where
primaquine is not routinely administered (e.g. Ethiopia), CQ
resulted in fewer early recurrent parasitemias than AL, which
could provide some hematologic and transmission benefits. This
supports the maintenance of current species-specific treatment
policy for Ethiopia [9].
With high recurrent parasitemia rates for both AL and CQ at
42 days following treatment, the addition of primaquine for radical
cure should be considered in all areas of Ethiopia as is currently
recommended by WHO [27]. Furthermore, with an increasing
number of reports showing that P. vivax infections can lead to
severe disease [55,56,57], country policies and practices that fail to
prevent substantial numbers of relapsing P. vivax illnesses need to
be reexamined. In Ethiopia, the addition of primaquine to CQ
decreased the cumulative incidence of therapeutic failure at day 28
by a life-table analysis method from 5.76% to 0.75% and the
cumulative risk of relapse at day 157 by a life-table method from
61.8% to 26.3% [44]. Along with continued surveillance of AL or
CQ drug resistance, the added benefit of co-administering
primaquine with AL or CQ should be explored urgently in
Ethiopia.
Table 5. Adverse events by treatment arm.
Patients with adverse events, n (%) Artemether-lumefantrine (N = 122) Chloroquine (N = 120)
Abdominal Pain 5 (4.1) 9 (7.5)
Anorexia 2 (1.6) 2 (1.7)
Cough 10 (8.2) 7 (5.8)
Diarrhea 6 (4.9) 5 (4.2)
Dizziness 5 (4.1) 1 (0.8)
Headache 4 (3.3) 4 (3.3)
Myalgia 6 (4.9) 2 (1.7)
Nausea/vomiting 9 (7.4) 13 (10.8)
Oral ulcers 10 (8.2) 15 (12.5)
Pruritus 4 (3.3) 7 (5.8)
Rash 4 (3.3) 2 (1.7)
doi:10.1371/journal.pone.0063433.t005
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